Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of- Illness Study Based on Disease Severity Jiří Klimeš, PharmD, Milan.

Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of- Illness Study Based on Disease Severity Jiří Klimeš, PharmD, Milan Vocelka, MSc, Liliana Šedová, MD, Tomáš Doležal, MD, PhD, Tomáš Mlčoch, MSc, Alena Petříková, PharmD, Jiří Vlček, PhD Value in Health Regional Issues Volume 4, Pages (September 2014) DOI: /j.vhri Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Overall and breakdown mean annual costs per patient according to functional impairment (HAQ category). DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory drugs. Value in Health Regional Issues 2014 4, 75-81DOI: ( /j.vhri ) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of- Illness Study Based on Disease Severity Jiří Klimeš, PharmD, Milan.

Podobné prezentace

Prezentace na téma: "Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of- Illness Study Based on Disease Severity Jiří Klimeš, PharmD, Milan."— Transkript prezentace:

Podobné prezentace

O projektu

Kontaktní formulář

Přihlásit se

Přihlásit se přes sociální síť:

Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of- Illness Study Based on Disease Severity Jiří Klimeš, PharmD, Milan.

Podobné prezentace

Prezentace na téma: "Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of- Illness Study Based on Disease Severity Jiří Klimeš, PharmD, Milan."— Transkript prezentace:

Podobné prezentace

O projektu

Kontaktní formulář